BioNTech SE’s founders will leave the company to start a new biotech focused on messenger RNA, the technology behind their blockbuster Covid-19 vaccine, dashing investors’ confidence in the firm’s ...

Last year, the High Court ruled that one of Moderna’s patents relating to the messenger RNA (mRNA) technology, which underpinned its COVID-19 vaccine, was valid and that Pfizer and BioNTech’s ...

The move comes as BioNTech shifts to being a multiproduct commercial biotech, allowing Ugur Sahin and Özlem Türeci to transition back into research on next-generation mRNA therapeutics.

LONDON (Reuters) -Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal. Last ...

Add Yahoo as a preferred source to see more of our stories on Google. A vial of the Pfizer/BioNTech Comirnaty vaccine against Covid-19 at a mass vaccination center on July 1, 2021 in Leipzig, Germany.

BioNTech's co-founders, Ugur Sahin and Oezlem Tuereci, will leave the company by 2026 to establish a new venture focused on next-generation mRNA drugs. Although BioNTech's stock plummeted following ...

BioNTech SE’s founders will leave the company to start a new biotech focused on messenger RNA, the technology behind their blockbuster Covid-19 vaccine.

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Coronavirus disease (COVID-19) vaccination campaign in Ronda LONDON (Reuters) -Pfizer and its German partner BioNTech ...